Drug
Isis 420915 Gsk 299872
Isis 420915 Gsk 299872: highest development phase Phase 2, developed by Ionis Pharmaceuticals. 1 trial record tracked on RxWires.
- Highest phase
- Phase 2
- Developer
- Ionis Pharmaceuticals
Trials
| Drug | Phase | Indication |
|---|---|---|
| Isis 420915/GSK 299872 NCT02627820 | Phase 2 | Amyloidosis |
Latest
No recent events.
Follow Isis 420915 Gsk 299872 on RxWires to get trial status changes, FDA actions, filings and patent dates as they happen.
Sourced from ClinicalTrials.gov, openFDA, SEC EDGAR and the FDA Orange Book. Not investment or medical advice.